Abstract
Dopamine dysregulation syndrome shares some core behavioral features with psychostimulant addiction, suggesting that dopamine replacement therapy can acquire psychostimulantlike properties in some patients with Parkinson disease (PD). We here report strong experimental evidence supporting this hypothesis in an α-synuclein rat model of PD. Although levodopa had no effect in controls, it acquired 2 prominent psychostimulantlike properties in Parkinsonian rats: (1) it produced intense reward on its own and in parallel (2) decreased interest in other nondrug reward. These 2 effects may combine to explain the addictive use of levodopa after loss of midbrain dopamine neurons in some PD patients.
Copyright © 2013 American Neurological Association.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenoviridae / genetics
-
Adenoviridae / metabolism
-
Animals
-
Antiparkinson Agents / pharmacology
-
Antiparkinson Agents / therapeutic use*
-
Conditioning, Operant / drug effects
-
Conditioning, Operant / physiology
-
Disease Models, Animal
-
Dopaminergic Neurons / drug effects
-
Dopaminergic Neurons / pathology*
-
Food Preferences / drug effects
-
Humans
-
Levodopa / pharmacology
-
Levodopa / therapeutic use*
-
Male
-
Mutation / genetics
-
Parkinson Disease / drug therapy*
-
Parkinson Disease / etiology
-
Parkinson Disease / genetics
-
Parkinson Disease / pathology*
-
Rats
-
Rats, Wistar
-
Reward
-
Saccharin / administration & dosage
-
Substantia Nigra / pathology*
-
Sweetening Agents / administration & dosage
-
Taste / drug effects
-
Transduction, Genetic
-
Tyrosine 3-Monooxygenase / metabolism
-
Ubiquitin / metabolism
-
alpha-Synuclein / genetics
-
alpha-Synuclein / toxicity
Substances
-
Antiparkinson Agents
-
Sweetening Agents
-
Ubiquitin
-
alpha-Synuclein
-
Levodopa
-
Tyrosine 3-Monooxygenase
-
Saccharin